NCT06607380View on ClinicalTrials.gov

A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 13, 2022

Primary Completion Date

April 10, 2023

Study Completion Date

April 17, 2023

Conditions
Tetanus
Interventions
BIOLOGICAL

TNM002

A single intramuscular (IM) gluteal injection

BIOLOGICAL

Adsorbed tetanus vaccine

A single IM deltoid injection

BIOLOGICAL

TNM002 + adsorbed tetanus vaccine

A single IM gluteal injection+ a single IM deltoid injection

Trial Locations (1)

255000

PKUCare Luzhong Hospital, Zibo

All Listed Sponsors
lead

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY